


## Endovion

<b>Cat. No.:</b>	HY-105917		
<b>CAS No.:</b>	265646-85-3		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>9</sub> BrF <sub>6</sub> N <sub>6</sub> O		
<b>Molecular Weight:</b>	495.18		
<b>Target:</b>	Chloride Channel		
<b>Pathway:</b>	Membrane Transporter/Ion Channel		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : 125 mg/mL (252.43 mM; Need ultrasonic)  
 H<sub>2</sub>O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration	Mass	Mass	Mass
1 mM	2.0195 mL	10.0973 mL	20.1947 mL	
5 mM	0.4039 mL	2.0195 mL	4.0389 mL	
10 mM	0.2019 mL	1.0097 mL	2.0195 mL	

Please refer to the solubility information to select the appropriate solvent.

### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution

## BIOLOGICAL ACTIVITY

### Description

Endovion (NS3728) is a pharmacological anion channel inhibitor (like chloride channel) and the specific VRAC/VSOAC blocker. Endovion (NS3728) is also an Anoctamin-1 (ANO 1) channel inhibitor<sup>[1][2]</sup>.

### IC<sub>50</sub> & Target

Chloride channel, VRAC/VSOAC<sup>[1]</sup>.  
 ANO1<sup>[2]</sup>.

### In Vitro

Endovion (NS3728, 10-100 μM) reduces TNFα-induced apoptosis and increases p53-protein level as well as downstream signaling, e.g., expression of p21<sup>Waf1/Cip1</sup>, Bax, Noxa, MDM2, and activation of Caspase-9/-3 in Cisplatin-sensitive cells<sup>[1]</sup>.  
 Endovion (NS3728, 10 μM) inhibits cell proliferation in Capan-1, AsPC-1 and BxPC-3 cell lines<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Western Blot Analysis<sup>[1]</sup>

Cell Line:	Wild-type, resistant, and transiently transfected A2780 cells.
Concentration:	10-100 $\mu$ M.
Incubation Time:	18 or 4.5 h.
Result:	Reduced the maximal taurine rate constant more than 90% compared with the untreated control cells. Resulted in an increased LRRC8A protein expression. Significantly reduced p53 and p21Waf1/Cip1 protein level in A2780WT cells.

#### Cell Proliferation Assay<sup>[2]</sup>

Cell Line:	Capan-1, AsPC-1, BxPC-3 and H6c7 cell lines.
Concentration:	10 $\mu$ M.
Incubation Time:	24 h.
Result:	Resulted in the most pronounced inhibition in all cell lines with 77 $\pm$ 26 % in Capan-1, 67 $\pm$ 9 % in AsPC-1, and 54 $\pm$ 8 % in BxPC-3 cells at +67 mV.

## REFERENCES

[1]. Sørensen BH, et al. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against CDDP-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. *Am J Physiol Cell Physiol.* 2016 Jun 1;310(11):C857-73.

[2]. Sauter DR, et al. ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). *Pflugers Arch.* 2015 Jul;467(7):1495-1508.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA